On April 28, KPMG China officially released "The 3rd KPMG China's Top 50 Bioinnovation Companies" list. Beijing Sungen Biomedical Technology Co., Ltd. (referred to as "Sungen Biomedical") was listed for its excellent scientific and technological innovation ability and breakthrough in R&D achievements.
This selection focuses on the cutting-edge technologies and commercial potential in the field of biomedicine. This honor is not only a high recognition of Sungen Biomedical's innovative achievements in the field of biotechnology, but also a powerful proof for its prominent innovative position in the pharmaceutical industry.
As an innovation-driven Biomedical technology company, Sungen Biomedical has been dedicated to the development of original antibody drugs since its establishment in 2018. Sungen Biomedical focuses on addressing unmet clinical needs and has built an international-level R&D system with high quality, including development of innovative monoclonal/bispecific antibody drugs, antibody-drug conjugates (ADC/AOC), original immunomodulatory ADC/AOC drugs, drugs based on AI technology, and technical platforms such as the evaluation system for the drugability of therapeutic antibodies. Up to now, Sungen Biomedical's innovative drug SGC001 has successively obtained clinical trial applications (INDs) from both FDA and CDE, and was granted Fast Track certification by the US FDA in March 2025. Currently, Phase Ib clinical trials are being conducted in multiple centers across China.
In the era of Biomedical innovation, Sungen Biomedical focuses on developing FIC (first-in-class) drugs, BIC (best-in-class) drugs, and valuable product pipelines, involving the treatment of cardiovascular and cerebrovascular diseases, tumors, and neurodegenerative diseases. With the launch of several blockbuster products, Sungen Biomedical will continue to provide original therapies for patients world-widely and accelerate the progress towards becoming a leading enterprise in the global field of antibody drugs.
Li Jing, Deputy General Manager of Sungen Biomedical
“We are honored to be included in the KPMG Bioinnovative 50 list along with many outstanding innovative enterprises. This is not only an endorsement of Sungen Biomedical but also an encouragement. We will continue to take original technology as the core, focus on unmet clinical needs, provide safer and more effective treatments for patients around the world, and fulfill the mission of improving human’s health with the power of technology.”
Updated: May 01, 2025
